At the time of writing, Cellectar Biosciences Inc [CLRB] stock is trading at $0.38, up 11.97%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CLRB shares have gain 20.59% over the last week, with a monthly amount glided 29.68%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ROTH Capital started tracking the stock assigning a Buy rating. Ladenburg Thalmann initiated its recommendation with a Buy and recommended $2.70 as its price target on December 21, 2016.
For the past year, the stock price of Cellectar Biosciences Inc fluctuated between $0.22 and $4.17. Currently, Wall Street analysts expect the stock to reach $12 within the next 12 months. Cellectar Biosciences Inc [NASDAQ: CLRB] shares were valued at $0.38 at the most recent close of the market. An investor can expect a potential return of 3057.89% based on the average CLRB price forecast.
Analyzing the CLRB fundamentals
Gross Profit Margin for this corporation currently stands at 0.32% with Operating Profit Margin at -156.13%, Pretax Profit Margin comes in at -135.23%, and Net Profit Margin reading is -135.05%. To continue investigating profitability, this company’s Return on Assets is posted at -1.2, Equity is -3.41 and Total Capital is -3.04. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.3454 points at the first support level, and at 0.3138 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.4002, and for the 2nd resistance point, it is at 0.4234.
Ratios To Look Out For
It is important to note that Cellectar Biosciences Inc [NASDAQ:CLRB] has a current ratio of 2.58. In addition, the Quick Ratio stands at 2.58 and the Cash Ratio stands at 1.69.
Transactions by insiders
Recent insider trading involved Longcor Jarrod, Chief Operating Officer, that happened on Jan 10 ’25 when 30000.0 shares were purchased.
